FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare
About | Sample | Privacy

Dynavax stock jumps on hep B data

Shares of Dynavax Technologies shot up 31 percent in after-hours trading after the developer announced that a late-stage trial of its experimental vaccine for hepatitis B showed that it performed better after two doses than three doses of GlaxoSmithKline's vaccine. Two doses of Hepislav protected 98 percent of volunteers compared to 25 percent protected by two doses of Glaxo's Engerix-B. Analysts say the data shows that Dynavax can successfully compete against Glaxo in the $1 billion hepatitis B market. Glaxo's vaccine is dominant, with $450 million in annual sales.

- check out the release on the trial data
- here's the AP report

Related Articles:
Dynavax touts trial data. Report
Dynavax, AstraZeneca ink $136M deal. Report
FDA approves hepatitis B drug. Report

More stories about FDA   AstraZeneca   GlaxoSmithKline   Drug Trials   sales and marketing   Vaccines   hepatitis B   Dynavax Technologies  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 24 + 23?
To combat spam, please solve the math question above.